Xtant Medical Collaborates with B2i Digital to Highlight Orthobiologics Innovation to Investors

Xtant Medical Holdings, a leader in the development and commercialization of regenerative medicine products, has entered into a partnership with B2i Digital to better communicate its orthobiologics innovation and market opportunity to investors. This collaboration aims to provide centralized, investor-focused content that highlights Xtant's comprehensive biologics platform and its potential for long-term growth in the medical technology sector.

The partnership underscores Xtant's vertically integrated model, which encompasses a wide range of products including bone-healing grafts, growth-factor biologics, and cellular allografts. With a strong research and development pipeline and several next-generation biologics slated for launch by 2025, Xtant is poised for significant margin improvement and sustainable growth. David Shapiro, CEO of B2i Digital, emphasized the strategic timing of this collaboration, noting Xtant's established distribution network and its position within a multi-billion-dollar market as key factors that make the company an attractive investment opportunity.

Sean Browne, CEO of Xtant Medical, expressed enthusiasm about the partnership, stating that it would enable the company to more effectively share its growth narrative and the value of its biologics platform with the investment community. Xtant's fiscal year 2024 revenue of $117.5 million, marking a 29% increase from the previous year, along with its extensive market access through hundreds of contracts and distributors, further solidifies its standing in the orthobiologics market.

This initiative not only highlights Xtant's commitment to innovation and growth but also serves as a bridge connecting the company with current and prospective investors, offering them deeper insights into its operations and future prospects. The collaboration between Xtant Medical and B2i Digital represents a strategic effort to educate and engage the investment community, showcasing the potential of orthobiologics in transforming patient care and the broader medical technology landscape.